Butyrylcholinesterase (BChE) is a non-specific enzyme with clinical pharmacological and toxicological significance, which was a renewed interest as therapeutic target in Alzheimer's disease (AD) nowadays. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.